<DOC>
	<DOCNO>NCT01056237</DOCNO>
	<brief_summary>An multi-site , randomize , prospective study compare efficacy safety multi-target therapy continuous induction maintenance treatment versus CTX- Aza therapy .</brief_summary>
	<brief_title>Long-Term Study Multi-target Therapy Maintenance Treatment Lupus Nephritis</brief_title>
	<detailed_description>Azathioprine ( AZA ) use maintenance therapy lupus nephritis many year . We compare efficacy safety multi-target therapy continuous induction maintenance treatment v CTX-Aza .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Patients sign write informed consent form 2 . SLE patient , age 1865 year , female male ; 3 . Patients diagnose lupus nephritis accord ISN/RPS 2003 classification criterion , class Ⅲ , Ⅳ , Ⅳ+Ⅴ , Ⅲ+Ⅴ Ⅴ LN renal biopsy 4 . All patient receive induction therapy 6 month multitherapy ( FK506 + MMF ) intravenous CTX pulse . 5 . Patients recruit receive partial remission complete remission 6 month induction therapy . Complete remission : proteinuria &lt; 0.4 g/24h , negative urine sediment , serum albumin &gt; 35 g/L , elevate scr &lt; 0.3mg/dl , extrarenal complication ; Partial remission : proteinuria &lt; 1.0 g/24h , urine RBC &lt; 50X104/ml without cast , serum albumin &gt; 30 g/L , elevate Scr &lt; 0.3mg/dl , extrarenal complication . 1 . Patients n't sign write informed consent form could obey protocol . 2 . Patients n't receive CR PR criterion . 3 . Patients impaired liver function , ALT/GPT AST/GOT twice normal upper limit active hepatitis . 4 . WBC &lt; 3000/mm3 peripheral blood . 5 . Patients central nervous system symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>